Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update

First case performed using the new FDA cleared Pure-Vu® EVS Gastro system, and expect to initiate broader market introductions by the end of 2023Pure-Vu EVS Gastro addresses the Upper GI market, an area of high